NOVEL IMMUNOTHERAPIES IN LYMPHOMA
With
Dr Sean Harrop
Clinical Haematology Fellow
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
He has research interests in novel immunotherapies in lymphoma, mechanisms that lead to immunotherapy resistance and the genetic mechanisms underlying the tumour microenvironment.
He has published in peer-reviewed journals, co-authored textbook chapters and presented at international conferences on clinical and translational research in lymphoma.
Dr Harrop’s upcoming PhD is funded by the Leukaemia Foundation, Haematology Society of Australia and New Zealand (HSANZ) and the Peter MacCallum Cancer Centre.
Source: Supplied and adapted
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
ROCK-induced early-onset bowel cancer progression
Professor Michael Samuel is a cell biologist whose research interest is in understanding how cancer mechanobiology influences the tumour microenvironment, thereby promoting tumour progression. He is Professor of Matrix Biology at the University of South Australia, Adelaide and heads the Tumour Microenvironment Laboratory at the Centre for Cancer Biology and the Cancer Mechanotherapies Laboratory at the Basil Hetzel Institute for Translational Health Research.
